Manage PAH With OPSYNVI®
Even when your symptoms appear stable, PAH may silently progress — starting OPSYNVI® helps you treat PAH by targeting two foundational pathways with a single pill.
What Is Pulmonary Arterial Hypertension (PAH)?
PAH is a progressive disease in which patients experience high blood pressure within the arteries connecting the heart and lungs. This condition can cause the muscles in your heart to stiffen and thicken, enlarging the right side and forcing it to work harder. PAH may silently progress and worsen over time, leading to right heart failure.
Understanding PAH: 3 Foundational Pathways
The blood vessels in the lungs produce naturally occurring substances known as nitric oxide, endothelin, and prostacyclin. When these substances are in proper balance, blood can flow freely through the healthy blood vessels. In PAH, these foundational pathways experience an imbalance, with either too little or too much of one or more of these substances leading the arterial walls to become stiff and narrow. There are medications available to treat each of these pathways.
Nitric Oxide Pathway
The body may not have enough nitric oxide to keep arteries from getting narrow. Medications target the nitric oxide pathway by helping to keep blood vessels open.
OPSYNVI® works here
Endothelin Pathway
Too much endothelin can cause blood vessels to narrow and tighten. Medications target the endothelin pathway by helping to block the extra endothelin that constricts blood vessels.
OPSYNVI® works here
Prostacyclin Pathway
The body may not make enough prostacyclin to keep arteries open. Medications target the prostacyclin pathway by helping to keep the arteries open.
Target 2 of 3 Foundational Pathways With OPSYNVI®
OPSYNVI® treats PAH by targeting two foundational pathways—nitric oxide and endothelin—with the combination of macitentan and tadalafil in a once-daily pill.
How Is PAH Classified?
Your PAH functional class is determined by the symptoms you experience and their impact on your daily activities.
4 Functional Classes
FC1 (I)
No symptoms during regular
physical activities.
FC2 (II)
Symptoms occur during ordinary physical activities.
There's a slight limitation in physical activity.
FC3 (III)
Symptoms arise with less than ordinary physical activity. There's a significant limitation in physical activity.
FC4 (IV)
Symptoms occur with any level of physical activity, including at rest.
There are independent* organizations available to help you learn more about PAH.
*Independent organizations not affiliated with Johnson & Johnson.
Pulmonary Hypertension Association
Visit WebsiteScleroderma Foundation
Visit WebsiteBlue Lips Foundation
Visit WebsiteTeam PHenomenal Hope
Visit WebsiteAmerican Lung Association
Visit WebsiteAmerican Heart Association
Visit WebsiteCOVID-19 and PAH
Visit the websites below for information regarding COVID-19 and PAH. If you are currently taking OPSYNVI®, please speak with your healthcare provider regarding any questions you may have.
Centers for Disease Control and Prevention (CDC)